In May 2016, Chinese investment group Creat Group agreed to acquire UK-based Bio Products Laboratory for 820 million GBP (1.1 billion USD).
Headquartered in Hertfordshire, Bio Products Laboratory is a plasma biotherapeutics company that provides therapeutics for conditions related to bleeding disorders, immune deficiencies and critical care.
Creat will invest an additional 100 million GBP into Bio Products Laboratory in order to expand its production capacity, access new markets and develop new products.
Commenting on the acquisition, Mr. Ng Yuk, CEO of Creat Group, said “We have come to know the management team at BPL well in recent years and have the highest respect for what they have achieved. We believe we can help BPL achieve its growth ambitions through our long-term investment approach and our deep knowledge of this sector.”
He also pointed out the benefits of the investment for the UK market, saying “Our additional investment will create new highly skilled jobs in the UK, as well as increase the supply of important plasma biotherapeutic products for the UK and globally, serving the needs of patients who depend on these lifesaving products.”
Chinese investors who are planning to make significant deployments in the global healthcare market often turn to trusted facilitators to source high-potential opportunities. Naseba has spent over a decade building close relationships with investors around the world, including China. Our analysts conduct daily phone calls with Chinese investors, and fully understand their needs and mandates.
On December 7th, 2016, in Shanghai, Naseba will be organising the European Healthcare Investment Meeting. At the meeting, pre-screened Chinese investors will be introduced to pre-qualified European healthcare opportunities.
Submit your business case:
Oops! We could not locate your form.
To learn more, contact:
Naseba investor introduction
+971 4 455 7954